Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 7/2019

01-07-2019 | Nutrition | Original Article

Inflammation–nutrition score predicts prognosis of patients with resectable hepatocellular carcinoma

Authors: Xiao-Chun Ni, Jie Xu, Yong Yi, Yi-Peng Fu, Xiao-Yan Cai, Gao Liu, Jin-Long Huang, Wei Gan, Shuang-Jian Qiu

Published in: International Journal of Clinical Oncology | Issue 7/2019

Login to get access

Abstract

Background

Various inflammation-based prognostic scores have been associated with poor survival in patients with hepatocellular carcinoma (HCC).

Methods

Data were collected retrospectively from 674 HCC patients who underwent curative resection. The correlation between INS (inflammation–nutrition score), BCLC (Barcelona Clinic Liver Cancer) stage and inflammatory indices and overall survival (OS) and disease free survival (DFS) was examined.

Results

An elevated INS was associated with both tumor and host clinical characteristics. The combination of INS and BCLC stage stratifies OS and DFS from 80% and 65% (INS = 0, stage A) to 0% (INS = 2, stage C). Univariate and multivariate analyses revealed that the INS was an independent predictor for OS and DFS, and was superior to inflammation-based scores. In addition, INS was demonstrated to be a prognostic factor for patients with early stage and had a higher AUC value in comparison with inflammation scores.

Conclusion

This study demonstrates that the INS is an independent marker of poor prognosis in patients with resectable HCC, especially for those with early stage, and it provides complimentary prognostic information to BCLC stage, and may aid in treatment strategy.
Appendix
Available only for authorised users
Literature
1.
Lindsey A, Torre M, Freddie Bray P et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108CrossRef
2.
Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 2(66):115–132CrossRef
3.
Ng KK, Lo CM, Liu CL et al (2008) Survival analysis of patients with transplantable recurrent hepatocellular carcinoma: implications for salvage liver transplant. Arch Surg 143(1):68–74CrossRefPubMed
4.
5.
McAllister SS, Weinberg RA (2014) The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol 16(8):717–727CrossRefPubMedPubMedCentral
6.
Proctor MJ, Morrison DS, Talwar D et al (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 47(17):2633–2641CrossRefPubMed
7.
Shrotriya S, Walsh D, Bennani-Baiti N et al (2015) C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review. PLoS One 10(12):e0143080CrossRefPubMedPubMedCentral
8.
Templeton AJ, McNamara MG, Šeruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106(6):dju124CrossRefPubMed
9.
Pang Q, Zhang JY, Xu XS et al (2015) Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence. World J Gastroenterol 21(18):5607–5621CrossRefPubMedPubMedCentral
10.
Chan AW, Chan SL, Wong GL et al (2015) Prognostic nutritional index (PNI) predicts tumor recurrence of very early/early stage hepatocellular carcinoma after surgical resection. Ann Surg Oncol 22(13):4138–4148CrossRefPubMed
11.
Lai Q, Castro Santa E, Rico Juri JM et al (2014) Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer. Transpl Int 27(1):32–41CrossRefPubMed
12.
Yamamura K, Sugimoto H, Kanda M et al (2014) Comparison of inflammation-based prognostic scores as predictors of tumor recurrence in patients with hepatocellular carcinoma after curative resection. J Hepato Biliary Pancreat Sci 21(9):682–688CrossRef
13.
Proctor MJ, Morrison DS, Talwar D et al (2011) An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 104(4):726–734CrossRefPubMedPubMedCentral
14.
Kinoshita A, Onoda H, Imai N et al (2013) The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer 13:52CrossRefPubMedPubMedCentral
15.
Pinato DJ, Stebbing J, Ishizuka M et al (2012) A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol 57(5):1013–1020CrossRefPubMed
16.
Nakamura M, Iwahashi M, Nakamori M et al (2014) New prognostic score for the survival of patients with esophageal squamous cell carcinoma. Surg Today 44(5):875–883CrossRefPubMed
17.
Arigami T, Okumura H, Matsumoto M et al (2015) Analysis of the fibrinogen and neutrophil-lymphocyte ratio in esophageal squamous cell carcinoma: a promising blood marker of tumor progression and prognosis. Medicine (Baltim) 94(42):e1702CrossRef
18.
Hirashima K, Watanabe M, Shigaki H et al (2014) Prognostic significance of the modified Glasgow prognostic score in elderly patients with gastric cancer. J Gastroenterol 49(6):1040–1046CrossRefPubMed
19.
Kawashima M, Murakawa T, Shinozaki T et al (2015) Significance of the Glasgow Prognostic Score as a prognostic indicator for lung cancer surgery. Interact Cardiovasc Thorac Surg 21(5):637–643CrossRefPubMed
20.
Takeno S, Hashimoto T, Shibata R et al (2014) The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor in patients with resectable gastric cancer. Oncology 87(4):205–214CrossRefPubMed
21.
Ishizuka M, Kubota K, Kita J et al (2011) Usefulness of a modified inflammation-based prognostic system for predicting postoperative mortality of patients undergoing surgery for primary hepatocellular carcinoma. J Surg Oncol 103(8):801–806CrossRefPubMed
22.
Van Dijk M, Pot GK (2016) The effects of nutritional interventions on recurrence in survivors of colorectal adenomas and cancer: a systematic review of randomised controlled trials. Eur J Clin Nutr 70(5):566–573CrossRefPubMed
23.
Pergialiotis V, Doumouchtsis SK, Perrea D et al (2016) The impact of underweight status on the prognosis of ovarian cancer patients: a meta-analysis. Nutr Cancer 68(6):918–925CrossRefPubMed
24.
Mantzorou M, Koutelidakis A, Theocharis S et al (2017) Clinical value of nutritional status in cancer: what is its impact and how it affects disease progression and prognosis? Nutr Cancer 69(8):1151–1176CrossRefPubMed
25.
Davis CJ, Sowa D, Keim KS et al (2012) The use of prealbumin and C-reactive protein for monitoring nutrition support in adult patients receiving enteral nutrition in an urban medical center. J Parenter Enter Nutr 36(2):197–204CrossRef
26.
Lee JL, Oh ES, Lee RW et al (2015) Serum albumin and prealbumin in calorically restricted, nondiseased individuals: a systematic review. Am J Med 128(9):1023.e1–1023.e22CrossRef
27.
Alifano M, Falcoz PE, Seegers V et al (2011) Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg 142(5):1161–1167CrossRefPubMed
28.
Kawai H, Ota H (2012) Low perioperative serum prealbumin predicts early recurrence after curative pulmonary resection for non-small-cell lung cancer. World J Surg 36(12):2853–2857CrossRefPubMed
29.
Zhang L, Su Y, Chen Z et al (2017) The prognostic value of preoperative inflammation-based prognostic scores and nutritional status for overall survival in resected patients with nonmetastatic Siewert type II/III adenocarcinoma of esophagogastric junction. Medicine (Baltim) 96(30):e7647CrossRef
30.
Han WX, Chen ZM, Wei ZJ et al (2016) Preoperative pre-albumin predicts prognosis of patients after gastrectomy for adenocarcinoma of esophagogastric junction. World J Surg Oncol 14(1):279CrossRefPubMedPubMedCentral
31.
Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10(21):7252–7259CrossRefPubMed
32.
Sun HC, Zhang W, Qin LX et al (2007) Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol 47(5):684–690CrossRefPubMed
33.
34.
Kinoshita A, Onoda H, Imai N et al (2015) C-reactive protein as a prognostic marker in patients with hepatocellular carcinoma. Hepatogastroenterology 62(140):966–970PubMed
35.
Proctor MJ, McMillan DC, Horgan PG et al (2015) Systemic inflammation predicts all-cause mortality: a glasgow inflammation outcome study. PLoS ONE 10(3):e0116206CrossRefPubMedPubMedCentral
36.
Abe T, Tashiro H, Hattori M et al (2016) Prediction of long-term survival by using the Glasgow Prognostic Score in patients with hepatocellular carcinoma after liver transplantation. Hepatol Res 46(7):622–633CrossRefPubMed
37.
Amri R, Bordeianou LG, Sylla P et al (2014) Obesity, outcomes and quality of care: body mass index increases the risk of wound-related complications in colon cancer surgery. Am J Surg 207(1):17–23CrossRefPubMed
38.
Balentine CJ, Wilks J, Robinson C et al (2010) Obesity increases wound complications in rectal cancer surgery. J Surg Res 163(1):35–39CrossRefPubMed
39.
Santoso JT, Barton G, Riedley-Malone S et al (2012) Obesity and perioperative outcomes in endometrial cancer surgery. Arch Gynecol Obstet 285(4):1139–1144CrossRefPubMed
40.
Tsai S, Choti MA, Assumpcao L et al (2010) Impact of obesity on perioperative outcomes and survival following pancreaticoduodenectomy for pancreatic cancer: a large single-institution study. J Gastrointest Surg 14(7):1143–1150CrossRefPubMed
41.
Bhayani NH, Hyder O, Frederick W et al (2012) Effect of metabolic syndrome on perioperative outcomes after liver surgery: a National Surgical Quality Improvement Program (NSQIP) analysis. Surgery 152(2):218–226CrossRefPubMed
42.
Suh B, Park S, Shin DW et al (2014) Low albumin-to-globulin ratio associated with cancer incidence and mortality in generally healthy adults. Ann Oncol 25(11):2260–2266CrossRefPubMed
43.
Alifano M, Mansuet-Lupo A, Lococo F et al (2014) Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancer. PLoS One 9(9):e106914CrossRefPubMedPubMedCentral
44.
Yang XR, Xu Y, Yu B et al (2010) High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 59(7):953–962CrossRefPubMed
45.
Fan ST, Mau Lo C, Poon RT et al (2011) Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg 253(4):745–758CrossRefPubMed
46.
Poon RT, Fan ST, Lo CM et al (2000) Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol 18(5):1094–1101CrossRefPubMed
47.
Torzilli G, Belghiti J, Kokudo N et al (2013) A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC East–West study group. Ann Surg 257(5):929–937CrossRefPubMed
48.
EASL-EORTC Clinical Practice Guidelines (2012) Management of hepatocellular carcinoma. J Hepatol 56(4):908–943CrossRef
49.
Guthrie GJ, Roxburgh CS, Farhan-Alanie OM et al (2013) Comparison of the prognostic value of longitudinal measurements of systemic inflammation in patients undergoing curative resection of colorectal cancer. Br J Cancer 109(1):24–28CrossRefPubMedPubMedCentral
50.
Okuno M, Ebata T, Yokoyama Y et al (2016) Evaluation of inflammation-based prognostic scores in patients undergoing hepatobiliary resection for perihilar cholangiocarcinoma. J Gastroenterol 51(2):153–161CrossRefPubMed
Metadata
Title
Inflammation–nutrition score predicts prognosis of patients with resectable hepatocellular carcinoma
Authors
Xiao-Chun Ni
Jie Xu
Yong Yi
Yi-Peng Fu
Xiao-Yan Cai
Gao Liu
Jin-Long Huang
Wei Gan
Shuang-Jian Qiu
Publication date
01-07-2019
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 7/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-019-01402-4

Other articles of this Issue 7/2019

International Journal of Clinical Oncology 7/2019 Go to the issue

Original Article

Use of direct oral anti-coagulants for the treatment of venous thromboembolism in patients with advanced cancer: a prospective observational study

Original Article

Oncologic and reproductive outcomes of cystectomy as a fertility-sparing treatment for early-stage epithelial ovarian cancer

Original Article

Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer

Original Article

Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients

Original Article

Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer

Original Article

Long-term outcomes and prognostic factors of pulmonary metastasectomy for osteosarcoma and soft tissue sarcoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits